Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2022-03-30 Regulatory Filings
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
Appendix 4G 22 pages 391.5KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed disclosure related to corporate governance practices, compliance with ASX Corporate Governance Council recommendations, and includes a key to where governance disclosures can be found. The document is not the corporate governance statement itself but a verification and key to disclosures, as required to be lodged alongside the annual report. It does not contain financial statements or management discussion of financial results. It is a regulatory compliance filing related to governance disclosures, not a full annual report or management report. Given the nature and content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2022-03-30 English
Date of Annual General Meeting 1 page 77.8KB
AGM Information Classification · 95% confidence The document is an announcement from Cyclopharm Limited regarding the date of their Annual General Meeting (AGM) and the closing date for director nominations. It references the ASX Listing Rule 3.13.1 and provides logistical details about the AGM and director nominations. There is no financial data, no detailed report, and the document is relatively short (2659 characters). It is clearly an announcement related to the AGM, not the AGM materials themselves or the voting results. Therefore, the document fits the category of AGM Information (AGM-R).
2022-03-15 English
Change of Director's Interest Notice 2 pages 205.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction (on-market trade), and dates. There is no financial performance data, earnings information, or report content. The document is a formal notification of a director's personal share transactions, which fits the definition of Director's Dealing filings.
2022-03-08 English
Preliminary Final Report 69 pages 539.5KB
Annual Report Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E' and contains detailed financial results for the year ended 31 December 2021. It includes company details, financial performance highlights, dividend information, and a Managing Director's Report with a comprehensive review of the financial year. The document references audited accounts in process and provides extensive financial data such as revenues, losses, cash position, and operational strategies. The presence of a Managing Director's Review and detailed financial statements indicates this is a comprehensive annual financial report. Appendix 4E is a common Australian regulatory form for preliminary final reports, which aligns with an Annual Report or a full-year financial report. The document is about 15,000 characters long, which is substantial and contains actual financial data, not just an announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K equivalent). FY 2021
2022-02-22 English
Dividend/Distribution - CYC 4 pages 25.0KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution by Cyclopharm Limited. It includes details such as the dividend amount, ex-date, record date, and payment date. The content is focused on announcing the dividend payment specifics rather than providing a full financial report or analysis. The document length is 4012 characters, which is relatively short and typical for a dividend announcement. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2022-02-22 English
CYC Results Summary 4 pages 158.7KB
Earnings Release Classification · 90% confidence The document is an announcement dated 23 February 2022 from Cyclopharm Limited reporting full year financial results for the fiscal year ending 31 December 2021. It includes detailed financial performance data such as record sales revenue, net loss before tax, cash balances, and dividend information. It also discusses operational highlights including USFDA regulatory approval progress, market expansion, and pipeline growth opportunities. The document contains substantive financial data and analysis for the full fiscal year, not just a brief summary or announcement of a report. It is not a transcript, proxy, or regulatory filing, but a comprehensive annual financial results announcement. Given the detailed financial results and business commentary for the full year, this document fits the definition of an Annual Report (10-K equivalent) or Annual Report type filing. However, since it is an ASX announcement and not a full statutory annual report, it aligns best with an Earnings Release (ER) or Annual Report (10-K) category. The length and detail suggest it is more than a simple earnings release, but since it is a full year results announcement with financial highlights and outlook, the best fit is Earnings Release (ER). FY 2021
2022-02-22 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.